Equities analysts expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to report sales of $830,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Proteostasis Therapeutics’ earnings, with the highest sales estimate coming in at $850,000.00 and the lowest estimate coming in at $800,000.00. Proteostasis Therapeutics reported sales of $1.55 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 46.5%. The firm is expected to issue its next earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Proteostasis Therapeutics will report full year sales of $3.67 million for the current fiscal year, with estimates ranging from $3.49 million to $3.84 million. For the next year, analysts expect that the firm will post sales of $3.52 million, with estimates ranging from $3.50 million to $3.53 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last issued its earnings results on Wednesday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Proteostasis Therapeutics had a negative net margin of 1,309.13% and a negative return on equity of 104.16%. The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1.16 million.

A number of research analysts have recently commented on the stock. Royal Bank of Canada upgraded shares of Proteostasis Therapeutics from a “sector perform” rating to an “outperform” rating in a research report on Thursday, October 18th. Zacks Investment Research upgraded shares of Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a research report on Thursday, October 18th. ValuEngine upgraded shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Finally, Piper Jaffray Companies assumed coverage on shares of Proteostasis Therapeutics in a research report on Monday, October 29th. They set an “overweight” rating and a $14.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Proteostasis Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $13.86.

PTI stock traded down $0.17 during midday trading on Monday, reaching $7.02. 659,377 shares of the company’s stock traded hands, compared to its average volume of 7,768,375. Proteostasis Therapeutics has a 52 week low of $1.41 and a 52 week high of $10.38. The stock has a market capitalization of $253.58 million, a price-to-earnings ratio of -3.00 and a beta of -3.25.

In related news, Director Franklin M. Berger bought 40,000 shares of the business’s stock in a transaction that occurred on Friday, October 26th. The stock was bought at an average cost of $6.75 per share, for a total transaction of $270,000.00. Following the completion of the transaction, the director now owns 266,162 shares of the company’s stock, valued at $1,796,593.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 19.80% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in PTI. BlackRock Inc. lifted its stake in Proteostasis Therapeutics by 3,693.4% in the second quarter. BlackRock Inc. now owns 1,807,717 shares of the company’s stock worth $5,043,000 after purchasing an additional 1,760,063 shares during the last quarter. Northern Trust Corp lifted its stake in Proteostasis Therapeutics by 526.1% in the second quarter. Northern Trust Corp now owns 269,451 shares of the company’s stock worth $752,000 after purchasing an additional 226,417 shares during the last quarter. Bailard Inc. lifted its stake in Proteostasis Therapeutics by 12.0% in the second quarter. Bailard Inc. now owns 582,400 shares of the company’s stock worth $1,625,000 after purchasing an additional 62,300 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Proteostasis Therapeutics in the second quarter worth $141,000. Finally, Bank of New York Mellon Corp lifted its stake in Proteostasis Therapeutics by 252.8% in the second quarter. Bank of New York Mellon Corp now owns 62,319 shares of the company’s stock worth $174,000 after purchasing an additional 44,653 shares during the last quarter. Institutional investors own 64.57% of the company’s stock.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

Recommended Story: Technical Analysis

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.